Correlation of E-cadherin Expression and the Sensitivity to EGFR-TKI Molecular Targeted Therapy
10.3870/yydb.2014.05.009
- VernacularTitle:钙黏蛋白表达与表皮生长因子受体分子靶向治疗敏感/耐药的相关性
- Author:
Rongchun XING
;
Jun ZHENG
;
Wei LIU
;
Rucheng YAO
- Publication Type:Journal Article
- Keywords:
E-cadherin;
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Resistance;
Targeted therapy
- From:
Herald of Medicine
2014;(5):582-585
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the correlation of E-cadherin expression and the sensitivity to EGFR-TKI molecular targeted therapy. Methods Eight kinds of cells,MCF-7,MDA-MB-231,T24,SiHa,H460,SK-HEP-1,MHCC97-H and THP-1 were treated with EGFR-TKI PD153035 and gefitinib,respectively,for 48 hours. The drug-sensitivity was detected by MTT,and the IC50 of cells were calculated. The E-cadherin protein were detected and compared. Results Followed with PD153035 and gefitinib treatment,the survival rates of MCF-7,MDA-MB-231,T24 and SiHa significantly reduced,and more E-cadherin protein expressed. However, the survival rates of the H460, SK-HEP-1, MHCC97-H, and THP-1 cells showed opposite results. Conclusion The sensitivity of epithelial cancer cells to EGFR-TKI is correlated with E-cadherin expression. E-cadherin may play a significant role on regulateing the sensitivity to EGFR-TKI molecular targeted therapy. E-cadherin is a key biomarker for recruiting appropriate patients for EGFR-TKI molecular targeted therapy.
